Volastra Therapeutics Announces First Patient Dosed in Phase I/II Clinical Trial of VLS-1488, One in a Portfolio of Novel and Differentiated KIF18A Inhibitors
NEW YORK--(BUSINESS WIRE)--Oct 30, 2023--
Source: eagletribune.com
📰 Pat Lorusso News
Pat Lorusso News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Pat Lorusso. Real-time updates on events, politics, business and more.